特应性皮炎：背景、目标与未来展望（超级应答者）
Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders).
作者信息
Ruiz-Villaverde Ricardo, Domínguez-Cruz Javier, Navarro-Triviño Francisco J, Galán-Gutiérrez Manuel, Armario-Hita Jose Carlos, Pereyra-Rodriguez Jose Juan
机构信息
Dermatology Department, Hospital Universitario San Cecilio, H.U. San Cecilio, Avda. Conocimiento 33, 18016 Granada, Spain.
Dermatology Department, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
出版信息
Life (Basel). 2022 Aug 4;12(8):1192. doi: 10.3390/life12081192.
Abstract
In this Special Issue entitled , we have tried to collect research of special interest related mainly to the incorporation of pathophysiological aspects and therapeutic novelties in this regard [...].
摘要
在这本名为《 》的特刊中，我们试图收集主要与这方面病理生理方面的纳入以及治疗新方法相关的特别感兴趣的研究[...]。
相似文献
1
Atopic Dermatitis: Background, Objectives and Future Perspectives (Superresponders).特应性皮炎：背景、目标与未来展望（超级应答者）
Life (Basel). 2022 Aug 4;12(8):1192. doi: 10.3390/life12081192.
2
Novelties in atopic dermatitis research.特应性皮炎研究的新进展。
Drug News Perspect. 2008 Oct;21(8):465-8.
3
Future perspectives in the treatment of atopic dermatitis.特应性皮炎治疗的未来展望。
J Dermatol. 2009 Jul;36(7):367-76. doi: 10.1111/j.1346-8138.2009.00662.x.
4
A Comprehensive Review of Phototherapy in Atopic Dermatitis: Mechanisms, Modalities, and Clinical Efficacy.特应性皮炎光疗的综合综述：作用机制、治疗方式及临床疗效
Cureus. 2024 Mar 25;16(3):e56890. doi: 10.7759/cureus.56890. eCollection 2024 Mar.
5
Importance of food in the control of inflammation in atopic dermatitis.食物在特应性皮炎炎症控制中的重要性。
Exp Ther Med. 2020 Dec;20(6):206. doi: 10.3892/etm.2020.9336. Epub 2020 Oct 14.
6
Keratinocytes: innate immune cells in atopic dermatitis.角质形成细胞：特应性皮炎中的固有免疫细胞。
Clin Exp Immunol. 2021 Jun;204(3):296-309. doi: 10.1111/cei.13575. Epub 2021 Feb 15.
7
Old drugs, new tricks: Emerging role of drug repurposing in the management of atopic dermatitis.老药新用：药物再利用在特应性皮炎治疗中的新作用。
Cytokine Growth Factor Rev. 2022 Jun;65:12-26. doi: 10.1016/j.cytogfr.2022.04.007. Epub 2022 May 9.
8
Characterization of Classical Flexural and Nummular Forms of Atopic Dermatitis in Childhood with Regard to Anamnestic, Clinical and Epidermal Barrier Aspects.探讨特应性皮炎在儿童时期的经典弯曲型和钱币状形态与既往病史、临床和表皮屏障方面的关系。
Acta Derm Venereol. 2022 Mar 8;102:adv00664. doi: 10.2340/actadv.v101.979.
9
Oxidative Stress and Phototherapy in Atopic Dermatitis: Mechanisms, Role, and Future Perspectives.特应性皮炎的氧化应激与光疗：机制、作用及未来展望。
Biomolecules. 2022 Dec 19;12(12):1904. doi: 10.3390/biom12121904.
10
Upadacitinib for moderate to severe atopic dermatitis.巴瑞替尼治疗中重度特应性皮炎。
Immunotherapy. 2023 Aug;15(11):799-808. doi: 10.2217/imt-2023-0037. Epub 2023 May 17.
引用本文的文献
1
Super Responders in Moderate-to-Severe Atopic Dermatitis Under Treatment with Dupilumab: An Explorative Real-World Study.使用度普利尤单抗治疗的中重度特应性皮炎超级反应者：一项探索性真实世界研究。
J Clin Med. 2025 May 16;14(10):3480. doi: 10.3390/jcm14103480.
2
Definition of the Concept of Super-responders in Atopic Dermatitis: A Spanish Delphi Consensus.特应性皮炎超级反应者概念的定义：西班牙德尔菲共识
Acta Derm Venereol. 2025 Mar 6;105:adv42240. doi: 10.2340/actadv.v105.42240.
3
Super-Responders in Moderate-Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives.古塞库单抗治疗中重度银屑病的超级应答者：误区、现状与未来展望
Life (Basel). 2022 Sep 10;12(9):1412. doi: 10.3390/life12091412.
本文引用的文献
1
Long-Term Effectiveness and Safety of Biologic and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review.生物制剂和小分子药物治疗中度至重度特应性皮炎的长期有效性和安全性：一项系统评价。
Life (Basel). 2022 Jul 30;12(8):1159. doi: 10.3390/life12081159.
2
Preservative Contact Hypersensitivity among Adult Atopic Dermatitis Patients.成年特应性皮炎患者中的防腐剂接触性超敏反应
Life (Basel). 2022 May 11;12(5):715. doi: 10.3390/life12050715.
3
Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases.度普利尤单抗在三种 2 型炎症性疾病中表现出快速起效。
J Allergy Clin Immunol Pract. 2022 Jun;10(6):1515-1526. doi: 10.1016/j.jaip.2022.02.026. Epub 2022 Mar 6.
4
Study of Hypersensitivity to in Patients with Atopic Dermatitis with Head and Neck Pattern: Is It Useful as a Biomarker and Therapeutic Indicator in These Patients?头颈部型特应性皮炎患者对[具体物质]超敏反应的研究：它能否作为这些患者的生物标志物和治疗指标？ （注：原文中“in Patients with Atopic Dermatitis with Head and Neck Pattern”里的“in”后面应该有具体物质，这里按照完整的翻译思路给出译文，需根据实际原文补充完整该物质）
Life (Basel). 2022 Feb 16;12(2):299. doi: 10.3390/life12020299.
5
Sexual Dysfunction and Atopic Dermatitis: A Systematic Review.性功能障碍与特应性皮炎：一项系统综述。
Life (Basel). 2021 Nov 29;11(12):1314. doi: 10.3390/life11121314.
6
Super responders to guselkumab treatment in moderate-to-severe psoriasis: a real clinical practice pilot series.中重度银屑病 Guselkumab 治疗的超级应答者：真实临床实践的初步系列研究。
Int J Dermatol. 2022 Aug;61(8):1029-1033. doi: 10.1111/ijd.15784. Epub 2021 Nov 3.
7
Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.度普利尤单抗为中度至重度特应性皮炎成人患者提供快速且持续的具有临床意义的缓解。
Acta Derm Venereol. 2021 Nov 10;101(11):adv00585. doi: 10.2340/actadv.v101.307.
8
Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis.生物制剂和小分子药物治疗中度至重度特应性皮炎的短期有效性和安全性：一项系统评价和网状Meta分析
Life (Basel). 2021 Sep 6;11(9):927. doi: 10.3390/life11090927.
9
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).古塞单抗治疗 IL-23 可能改变银屑病发病机制：中重度斑块型银屑病患者的 3b 期、随机、双盲、多中心研究的原理和研究方案（GUIDE）。
BMJ Open. 2021 Sep 13;11(9):e049822. doi: 10.1136/bmjopen-2021-049822.
10
Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis.中重度斑块型银屑病患者接受替度鲁单抗治疗早期 PASI 应答的临床意义和预测价值。
J Dermatolog Treat. 2022 May;33(3):1670-1675. doi: 10.1080/09546634.2021.1898528. Epub 2021 Mar 18.
Zotero 插件